U.S. markets closed

Tocagen Inc. (TOCA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.2600-0.0500 (-3.82%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3100
Open1.2700
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range1.2200 - 1.5000
52 Week Range0.4220 - 28.0499
Volume761,405
Avg. Volume50,760
Market Cap2.009M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateApr 23, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Forte Biosciences, Inc. Announces Issuance of New U.S. Patent

      FORTE BIOSCIENCES, INC. ANNOUNCES ISSUANCE OF NEW U.S. PATENT

    • Tocagen Announces Change to Virtual Format for Special Meeting of Stockholders
      PR Newswire

      Tocagen Announces Change to Virtual Format for Special Meeting of Stockholders

      Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, it is changing its special meeting of stockholders related to its previously announced proposed merger with Forte Biosciences, Inc. (the "Special Meeting") to a virtual-only format that will be held via live audio webcast.

    • Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results
      PR Newswire

      Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results

      Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019.